Pancreatic Cancer Research

ResearcherMie UniversityActive in the last 2 years

Aoi Hayasaki

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7189-357X; OpenAlex author ID A5072040203. Sources: OpenAlex.

Their work

Papers
25
Trials
0
Grants
0
Labs led
0
Collaborators
64
Papers, trials and grants by year

2017: 1 paper · 2018: 3 papers · 2019: 4 papers · 2020: none · 2021: 3 papers · 2022: 4 papers · 2023: 1 paper · 2024: 2 papers · 2025: 5 papers · 2026: 2 papers

Papers 25

  1. Prognostic Significance of Portal Vein Tumor Thrombus in Pancreatic Ductal Adenocarcinoma Treated With Chemoradiotherapy. Co-author DOI 10.1002/ags3.70186↗
  2. Conversion surgery for unresectable pancreatic ductal adenocarcinoma with liver metastasis at initial diagnosis: a nationwide multicenter study. Co-author DOI 10.1007/s00535-026-02432-2↗
  3. Long-term survival analysis based on tumor location in patients with pancreatic ductal adenocarcinoma who underwent pancreatectomy following neoadjuvant chemor… Co-author DOI 10.1007/s00423-025-03609-8↗
  4. Surgical strategies for locally advanced pancreatic cancer following gemcitabine plus S-1-based chemoradiotherapy. Co-author DOI 10.1016/j.suronc.2025.102269↗
  5. Prognostic impacts of biological and conditional factors in patients with anatomically resectable pancreatic adenocarcinoma treated with preoperative chemoradi… Co-author DOI 10.1097/md.0000000000042441↗
  6. Tumor Budding Is an Independent Adverse Prognostic Factor of Pancreatic Ductal Adenocarcinoma Patients Treated by Resection After Preoperative Chemoradiotherap… Co-author DOI 10.1097/mpa.0000000000002440↗
  7. Impact of Surgical Resection After Induction Gemcitabine Plus S-1-Based Chemoradiotherapy in Patients with Locally Advanced Pancreatic Ductal Adenocarcinoma: A… Co-author DOI 10.3390/cancers17061048↗
  8. Prognostic impact of the distance from the anterior surface to tumor cells in pancreatoduodenectomy with neoadjuvant chemoradiotherapy for pancreatic ductal ad… Co-author DOI 10.1371/journal.pone.0307876↗
  9. Peritoneal washing cytology status as a crucial prognostic determinant in patients with localized pancreatic ductal adenocarcinoma who underwent curative-inten… Co-author DOI 10.1371/journal.pone.0309834↗
  10. Extrapancreatic extension is a better adverse prognostic factor than tumor size in patients with localized pancreatic ductal adenocarcinoma treated with chemor… Co-author DOI 10.1016/j.hpb.2023.06.015↗
  11. Concomitant splenic artery ligation has no preventive effect on left-sided portal hypertension following pancreaticoduodenectomy with the resection of the port… Co-author DOI 10.1002/ags3.12545↗
  12. Role of Serum Carcinoma Embryonic Antigen (CEA) Level in Localized Pancreatic Adenocarcinoma: CEA Level Before Operation is a Significant Prognostic Indicator … Co-author DOI 10.1097/sla.0000000000004148↗
  13. Predictive risk factors for early recurrence in patients with localized pancreatic ductal adenocarcinoma who underwent curative-intent resection after preopera… Co-author DOI 10.1371/journal.pone.0264573↗
  14. Involvement of superior mesenteric vein and superior mesenteric artery is adverse prognostic factors in patients with localized pancreatic ductal adenocarcinom… Co-author DOI 10.21203/rs.3.rs-2229927/v1↗
  15. Clinical significance and predictors of complete or near-complete histological response to preoperative chemoradiotherapy in patients with localized pancreatic… Co-author DOI 10.1016/j.pan.2021.08.011↗
  16. Phase I Study of Preoperative Chemoradiotherapy Using Gemcitabine Plus Nab-Paclitaxel for Patients Who Have Localized Pancreatic Ductal Adenocarcinoma With Con… Co-author DOI 10.1097/mpa.0000000000001902↗
  17. Improving the Prognosis of Pancreatic Cancer Through Early Detection: Protocol for a Prospective Observational Study. Co-author DOI 10.2196/26898↗
  18. The clinical impact of portal venous patency ratio on prognosis of patients with pancreatic ductal adenocarcinoma undergoing pancreatectomy with combined resec… Co-author DOI 10.1016/j.pan.2019.01.020↗
  19. Comparative Study Between Gemcitabine-Based and Gemcitabine Plus S1-Based Preoperative Chemoradiotherapy for Localized Pancreatic Ductal Adenocarcinoma, With S… Co-author DOI 10.1097/mpa.0000000000001227↗
  20. Clinical Significance of Plasma Apolipoprotein-AII Isoforms as a Marker of Pancreatic Exocrine Disorder for Patients with Pancreatic Adenocarcinoma Undergoing … Co-author DOI 10.1155/2019/5738614↗
  21. Prognostic Nutritional Index After Chemoradiotherapy Was the Strongest Prognostic Predictor Among Biological and Conditional Factors in Localized Pancreatic Du… Co-author DOI 10.3390/cancers11040514↗
  22. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Co-author DOI 10.1016/j.pan.2017.11.011↗
  23. Clinical Significance of Histological Effect and Intratumor Stromal Expression of Tenascin-C in Resected Specimens After Chemoradiotherapy for Initially Locall… Co-author DOI 10.1097/mpa.0000000000001022↗
  24. Survival Analysis in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Chemoradiotherapy Followed by Surgery According to the International Consensus o… Co-author DOI 10.3390/cancers10030065↗
  25. [I. The Efficacy of Preoperative Adjuvant Treatment for Pancreatic Ductal Adenocarcinoma Based on the Resectability Criteria according to JPS 7th]. Co-author PMID 29066676↗

Closest collaborators

The 25 strongest of 64 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Masashi Kishiwada · 24 shared papers, 2017–2026 · strength 3.49
  2. Shugo Mizuno · 23 shared papers, 2018–2026 · strength 3.40
  3. Yasuhiro Murata · 22 shared papers, 2017–2026 · strength 3.16
  4. Naohisa Kuriyama · 20 shared papers, 2018–2026 · strength 2.97
  5. Takahiro Ito · 11 shared papers, 2018–2025 · strength 1.93
  6. Kazuyuki Gyoten · 11 shared papers, 2021–2025 · strength 1.78
  7. Shuji Isaji · 14 shared papers, 2017–2023 · strength 1.36
  8. Benson Kaluba · 6 shared papers, 2022–2025 · strength 1.14
  9. Hiroyuki Sakurai · 11 shared papers, 2018–2022 · strength 1.11
  10. Toru Shinkai · 6 shared papers, 2017–2025 · strength 0.88
  11. Miki Usui · 3 shared papers, 2024–2026 · strength 0.74
  12. Hiroyuki Kato · 8 shared papers, 2017–2022 · strength 0.68
  13. Yoshinori Azumi · 6 shared papers, 2018–2019 · strength 0.47
  14. Masatoshi Watanabe · 2 shared papers, 2024–2025 · strength 0.45
  15. Takuya Yuge · 1 shared paper, 2024 · strength 0.20
  16. Hideki Motobayashi · 1 shared paper, 2026 · strength 0.18
  17. Joe Matsumoto · 1 shared paper, 2026 · strength 0.18
  18. Yosuke Inoue · 1 shared paper, 2026 · strength 0.18
  19. Masaaki Murakawa · 1 shared paper, 2026 · strength 0.18
  20. Sohei Satoi · 1 shared paper, 2026 · strength 0.18
  21. Masamichi Hayashi · 1 shared paper, 2026 · strength 0.18
  22. Takayoshi Nakajima · 1 shared paper, 2026 · strength 0.18
  23. Yoshitaro Shindo · 1 shared paper, 2026 · strength 0.18
  24. Masafumi Imamura · 1 shared paper, 2026 · strength 0.18
  25. Keiko Kamei · 1 shared paper, 2026 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.